HUB Investment Partners LLC Cuts Stake in United Therapeutics Co. (NASDAQ:UTHR)

HUB Investment Partners LLC lowered its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 19.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 695 shares of the biotechnology company’s stock after selling 165 shares during the period. HUB Investment Partners LLC’s holdings in United Therapeutics were worth $245,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Signaturefd LLC increased its stake in shares of United Therapeutics by 4.7% during the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 30 shares in the last quarter. Parallel Advisors LLC increased its stake in shares of United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock worth $385,000 after purchasing an additional 30 shares in the last quarter. Great Lakes Advisors LLC increased its stake in shares of United Therapeutics by 1.6% during the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock worth $697,000 after purchasing an additional 31 shares in the last quarter. Oregon Public Employees Retirement Fund increased its stake in shares of United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after purchasing an additional 33 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its stake in shares of United Therapeutics by 0.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock worth $1,761,000 after purchasing an additional 39 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now directly owns 5,528 shares in the company, valued at $1,966,696.56. This represents a 4.41 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $356.68, for a total transaction of $3,566,800.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $919,164.36. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 90,255 shares of company stock worth $32,614,521. 11.90% of the stock is currently owned by insiders.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $312.99 on Friday. The company’s 50-day moving average is $345.10 and its two-hundred day moving average is $357.02. United Therapeutics Co. has a 1-year low of $221.53 and a 1-year high of $417.82. The firm has a market capitalization of $14.06 billion, a price-to-earnings ratio of 13.75, a PEG ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same period in the prior year, the business posted $4.36 EPS. As a group, equities analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.